STOCKWATCH: Orphan and generic drugs diverge
This article was originally published in Scrip
At least two themes emerged from last week’s JP Morgan Conference in San Francisco. At the premium pricing end of the pharmaceutical market, the continuing push for orphan drugs is intensifying and at the opposite end of the market, the management of generics companies are planning how to handle the end of the patent cliff.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.